Portable Devices for Spotting Long-Term Illness Early in Clinics
Tests handheld ultrasound and blood sugar devices to find chronic diseases sooner.
Plain-language title generated from the registry record
Registry title: Truway Diagnostic Tools in Primary Care
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- Truway Health, Inc.New York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Truway Health, Inc.
- Trial code
- NCT07209527
- Record updated
- 5 November 2026
- Original description
This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings. Conducted as a prospective interventional trial, 200 participants will be assigned to use these devices versus standard care over a 6-month period. The primary outcome is improved diagnostic accuracy and patient outcomes. The study, led by Truway Health, Inc., aims to enhance accessible healthcare solutions starting at a New York site, with potential expansion to Miami.Read full original descriptionShow less
Evaluation of Truway Health-Sourced Portable Diagnostic Devices for Early Detection of Chronic Conditions in Outpatient Primary Care Settings: A Prospective Interventional Study
This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings. Conducted as a prospective interventional trial, 200 participants will be assigned to use these devices versus standard care over a 6-month period. The primary outcome is improved diagnostic accuracy and patient outcomes. The study, led by Truway Health, Inc., aims to enhance accessible healthcare solutions starting at a New York site, with potential expansion to Miami.
Inclusion: Age 18 to 75 years, inclusive; Ability to understand the study procedures and provide written informed consent; Diagnosis of the target condition according to established clinical or diagnostic criteria; Stable treatment regimen (pharmacologic or non-pharmacologic) for at least 4 weeks prior to screening; Willingness and ability to comply with all study visits, procedures, and follow-up assessments -.
Exclusion: Known hypersensitivity to any components of the investigational intervention; Uncontrolled or unstable comorbid conditions (for example, cardiovascular, hepatic, renal, or psychiatric disorders); Cognitive impairment or language barrier that would preclude valid informed consent or reliable reporting; Pregnancy or breastfeeding at the time of enrollment; Participation in another interventional clinical trial within the past 3 months; -.